JPMorgan Chase & Co. increased its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI – Free Report) by 127.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,058 shares of the company’s stock after purchasing an additional 2,272 shares during the quarter. JPMorgan Chase & Co.’s holdings in Sanara MedTech were worth $123,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of SMTI. State Street Corp boosted its holdings in Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after purchasing an additional 4,932 shares during the last quarter. Barclays PLC increased its position in shares of Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after buying an additional 4,376 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Sanara MedTech by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after acquiring an additional 3,755 shares in the last quarter. 8.10% of the stock is currently owned by institutional investors and hedge funds.
Sanara MedTech Trading Down 1.4 %
NASDAQ SMTI opened at $36.33 on Monday. The firm’s 50-day moving average is $34.74 and its two-hundred day moving average is $33.24. The stock has a market capitalization of $317.52 million, a P/E ratio of -36.70 and a beta of 1.55. Sanara MedTech Inc. has a 12 month low of $26.00 and a 12 month high of $40.75. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on SMTI shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $44.00 price objective on shares of Sanara MedTech in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Sanara MedTech in a report on Thursday, January 23rd.
Read Our Latest Report on Sanara MedTech
Sanara MedTech Profile
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Featured Stories
- Five stocks we like better than Sanara MedTech
- What is the Nasdaq? Complete Overview with History
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- What is a Stock Market Index and How Do You Use Them?
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Buy P&G Now, Before It Sets A New All-Time High
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.